Acetylcysteine zidrimer is under clinical development by Orpheris and currently in Phase I for Parkinson’s Disease. According to GlobalData, Phase I drugs for Parkinson’s Disease have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Acetylcysteine zidrimer’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Acetylcysteine zidrimer overview
Acetylcysteine zidrimer (OP-101) is under development for the treatment of childhood cerebral andrenoleukodystrophy (ccALD), Parkinson's disease, Amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), hyperinflammation. It is administered through intravenous and subcutaneous route. The therapeutic candidate is a new chemical entity. It constitutes of hydroxyl poly (amidoamine) (PAMAM) dendrimer conjugated to N-acetyl cysteine (NAC) with a glutathione (GSH)-cleavable disulfide linkers. It is acts by targeting ikappaB kinase and nuclear factor kappa B and developed based on hydroxyl dendrimer technology.
It was also under development for the treatment of cerebral palsy, Huntington disease, neonatal brain injury (NBI) and other neuroinflammatory diseases and coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), hypoxemia and acute respiratory distress syndrome.
For a complete picture of Acetylcysteine zidrimer’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
